Table 3.
Summary of GBS vaccines in clinical trials.
| Vaccine Candidate | Basic Components | Clinical Trial | Reference |
|---|---|---|---|
| Native polysaccharide vaccines | Capsule polysaccharide (CPS) | Ineffective | [103] |
| GBS glycoconjugate vaccine | Capsule polysaccharide (CPS) | Phase I | [104,105] |
| Trivalent (Ia, Ib, and III) CRM197 conjugate vaccine | Capsule polysaccharide (CPS) | Phase Ib/II | [106] |
| Pentavalent conjugate vaccine (Ia, Ib, II, III, and V) | Capsule polysaccharide (CPS) | Phase I/II | [107] |
| Hexavalent vaccines (Ia, Ib, II, III, IV, V) | Capsule polysaccharide (CPS) | Phase I/II | [99] |
| Prototype recombinant alpha-like protein subunit vaccine (GBS-NN) | Highly immunogenic N-terminal domains of Alpha C and Rib (GBS-NN) | Phase I | [99,108,109] |